KNTP.F Stock Overview
A clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Kintor Pharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.16 |
| 52 Week High | HK$0.30 |
| 52 Week Low | HK$0.084 |
| Beta | -0.098 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -98.64% |
| 5 Year Change | n/a |
| Change since IPO | -87.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| KNTP.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 2.2% |
| 1Y | n/a | 16.2% | 31.7% |
Return vs Industry: Insufficient data to determine how KNTP.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how KNTP.F performed against the US Market.
Price Volatility
| KNTP.F volatility | |
|---|---|
| KNTP.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: KNTP.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KNTP.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 175 | Youzhi Tong | www.kintor.com.cn |
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in researching, developing, and commercializing therapeutic drugs for dermatology and tumors indications with the unmet medical needs in the People’s Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia and acne vulgaris; and Pruxelutamide (GT0918), a second-generation androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer, as well as AR-PROTAC Compound (GT20029). The company is developing Pruxelutamide (GT0918), a second generation androgen receptor (AR) for the metastatic castration-resistant prostate cancer, COVID-19, and AR+ metastatic breast cancer; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer; GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC); and ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours.
Kintor Pharmaceutical Limited Fundamentals Summary
| KNTP.F fundamental statistics | |
|---|---|
| Market cap | US$59.51m |
| Earnings (TTM) | -US$127.00m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs KNTP.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KNTP.F income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥41.10m |
| Gross Profit | -CN¥41.10m |
| Other Expenses | CN¥879.10m |
| Earnings | -CN¥920.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 59.8% |
How did KNTP.F perform over the long term?
See historical performance and comparison